A5075122115- Asthma and respiratory diseases
- Respiratory and Cough-Related Research
- Inhalation and Respiratory Drug Delivery
- Tryptophan and brain disorders
- Treatment of Major Depression
- Alcoholism and Thiamine Deficiency
- Chronic Disease Management Strategies
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Human Health and Disease
- Psychology Research and Bibliometrics
- Child and Adolescent Psychosocial and Emotional Development
- Folate and B Vitamins Research
- Maternal Mental Health During Pregnancy and Postpartum
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Respiratory viral infections research
- Breastfeeding Practices and Influences
- Allergic Rhinitis and Sensitization
- Eosinophilic Esophagitis
- Stress and Burnout Research
- Health, psychology, and well-being
AstraZeneca (Spain)
2018-2023
Hospital Vargas
2007-2008
The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated benralizumab in a real-world setting Spain.ORBE (NCT04648839) was an observational, retrospective cohort SEA who had been prescribed benralizumab. Demographic data 204 were collected 12 months prior initiation (baseline) at follow-up. Exacerbation rate, symptoms, maintenance oral corticosteroid (OCS) use lung function evaluated, among other variables.A...
<i>Objective(s):</i> Folic acid, a micronutrient supporting the natural defense system, may elevate antidepressant responses, although lymphocyte serotonergic system has not been explored in folate-supplemented depressed patients. <i>Methods:</i> Twenty-seven patients were randomly assigned to groups receiving fluoxetine (20 mg) and folic acid (10 mg/day) or placebo for 6 weeks. Clinical outcome was assessed according Hamilton Depression Rating Scale (HDRS) at...
Abstract Background Benralizumab, a monoclonal antibody targeting the human interleukin-5 (IL-5) receptor (IL-5R), was used before marketing authorisation in Spain real world setting as part of an early-access programme (EAP) to treat patients with severe eosinophilic asthma prior insufficient response or intolerance anti-IL5 treatment (mepolizumab reslizumab). The objective this study is describe patient profile candidate for and assess benralizumab effectiveness. Methods This...
Objective: We determined the percentage of patients with severe asthma and exacerbations evaluated costs disease based on blood eosinophil counts.Methods: A retrospective observational study review medical records in Spain was carried out. Patients ≥18 years age requiring care during 2014-2015; diagnosed at least 2 continuous (at one year prior to index date defined as first medication prescription after date) were included. Study groups: counts <300 cells/μl ≥300 cells/μl. Main variables:...
Our aim was to evaluate the relationship between clinical factors of asthma and use reliever medication.We performed an observational cross-sectional study in Spain. The population comprised patients aged ≥12 years diagnosed with persistent according criteria Global Initiative for Asthma receiving maintenance treatment at least 12 months. Use medication classified as low (LURM) (≤2 times/wk) high (HURM) (≥3 times/wk). A variety variables patient-reported outcomes (PROs) were recorded (eg,...
Severe asthma treatment with oral corticosteroids (OCS) added to inhaled and a long-acting β2-agonist (ICS-LABA) may result in more burden increased adverse effects.This ambispective multicenter observational study aimed at describing the clinical patients severe on stable high-dose ICS-LABA who received OCS during ≥6 months (maintenance group) or ≥2 cycles previous 12 (bursts group). Data collection comprised retrospective 12-month baseline period 2 follow-up visits 3 6 months.Eighty-nine...
To explore and understand the experiences of patients with severe asthma throughout their patient journey. Qualitative ethnographic study based on an approach. Barcelona, Sevilla Madrid. Ten adult (>18 years) persons (six females four males) diagnosed were selected from public healthcare settings by purposive sampling. Semi-structured in-depth interviews performed expert anthropologist in patients' homes. Data was collected using a video audio recorder analyzed three researchers sense-making...
<b>Background:</b> Severe asthma treatment with oral corticosteroids (OCS) added to ICS-LABA combination, may imply poor control, elevated disease burden and increased adverse reactions <b>Aims:</b> Describe the medical in patients severe uncontrolled treated high doses of frequent or chronic OCS use Spain <b>Methods:</b> This 6-month observational, prospective, multicentre nation-wide study, included adults patients, stable high-dose ICS-LABA, who received (1:2 proportion) over 6 months...